Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure

Haehling, Stephan von; Jankowska, Ewa A.; Morgenthaler, Nils G.; Vassanelli, Corrado; Zanolla, Luisa; Rozentryt, Piotr; Filippatos, Gerasimos; Doehner, Wolfram; Koehler, Friedrich; Papassotiriou, Jana; Kremastinos, Dimitrios Th.; Banasiak, Waldemar; Struck, Joachim; Ponikowski, Piotr; Bergmann, Andreas; Anker, Stefan D.

doi:10.1016/j.jacc.2007.08.012

Cited by 140 publications

(105 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In subgroup analyses, MRproANP measurements added to the utility of NTproBNP in patients with intermediate BNP values and with obesity. Supporting these findings are the results of another study, which evaluated the prognostic value of MR-pro-ANP serum concentrations for all-cause mortality in chronic heart failure patients; at 48 months of follow-up, MR-proANP significantly outperformed NTproBNP (AUC, 0.79 vs 0.75, P ϭ 0.03) (28 ).…”

Section: Mr-proanp and Nt-probnp In Stable Cvdmentioning

confidence: 71%

Prognostic Value of Midregional Pro–A-Type Natriuretic Peptide and N-Terminal Pro–B-Type Natriuretic Peptide in Patients with Stable Coronary Heart Disease Followed over 8 Years

et al. 2014

View full text Add to dashboard Cite

BACKGROUND:Pathophysiological studies suggest that A-type natriuretic peptides (ANPs) might provide valuable information beyond B-type natriuretic peptides (BNPs) about cardiac dysfunction in patients with coronary heart disease (CHD). We aimed to assess the predictive value of midregional pro-A-type natriuretic peptide (MR-proANP) for recurrent cardiovascular disease (CVD) events in stable CHD patients for whom information on N-terminal proBNP (NTproBNP) was already available.

show abstract

Section: Mr-proanp and Nt-probnp In Stable Cvdmentioning

confidence: 71%

Prognostic Value of Midregional Pro–A-Type Natriuretic Peptide and N-Terminal Pro–B-Type Natriuretic Peptide in Patients with Stable Coronary Heart Disease Followed over 8 Years

et al. 2014

View full text Add to dashboard Cite

show abstract

“…All 3 studies performed ROC curve analyses. In the study of patients with chronic heart failure, no difference between the 2 peptides was observed after 12 and 24 months of follow-up (14 ). The difference became significant at 48 months, with areas under the ROC curve of 0.79 and 0.75 for MR-proANP and NT-proBNP, respectively (P ϭ 0.03).…”

Section: Resultsmentioning

confidence: 96%

Comparison of Midregional Pro–A-Type Natriuretic Peptide and the N-Terminal Pro–B-Type Natriuretic Peptide for Predicting Mortality and Cardiovascular Events

et al. 2012

Self Cite

View full text Add to dashboard Cite

BACKGROUND: N-terminal pro-B-type natriuretic peptide (NT-proBNP) provides prognostic information on mortality and future cardiovascular events for individuals from the general population. A novel immunoassay was recently developed that measures a midregional fragment of pro-A-type natriuretic peptide (MR-proANP). We compared the capabilities of MRproANP and NT-proBNP for predicting mortality and cardiovascular events in a population-based study.

show abstract

“…Both automated assays are based on the sandwich chemiluminescence assays, which are described in detail elsewhere9, 10 and which have been used in other studies 9, 11, 12, 13…”

Section: Methodsmentioning

confidence: 99%

Comparative accuracy of NT‐proBNP and MR‐proANP for the diagnosis of acute heart failure in dyspnoeic patients

et al. 2017

View full text Add to dashboard Cite

AimsTo compare the performance of the natriuretic peptides (NPs) NT‐proBNP and MR‐proANP for the diagnosis of acute heart failure (AHF) in subsets of conditions potentially confounding the interpretation of NPs.Methods and resultsWe studied 312 patients, presenting to the emergency department with new onset of dyspnoea or worsening of chronic dyspnoea within the last 2 weeks. Performance of NPs for the diagnosis of AHF was tested and compared using C‐statistics in the entire cohort and in conditions previously described to confound interpretation of NPs such as older age, renal failure, obesity, atrial fibrillation or paced rhythm, and in the NT‐proBNP grey zone. AHF was diagnosed in 139 patients. In the entire cohort, the diagnostic performance of NT‐proBNP was comparable with that of MR‐proANP. Receiver operating characteristic analysis demonstrated that optimal diagnostic cut‐offs were higher in the presence of older age, kidney failure or rhythm disorder. However, there were no statistically relevant differences between the receiver operating characteristic curves analysed in the total population and those studied in the pre‐specified subsets severe kidney failure, advanced age, obesity, atrial fibrillation and paced rhythm, and grey zone NT‐proBNP values. Moreover, the diagnostic performance of NT‐proBNP was comparable with that of MR‐proANP in the subsets.ConclusionsThe performance of NT‐proBNP and MR‐proANP for AHF is comparable in the total population as well as in the subsets with potentially confounding characteristics such as older age, renal dysfunction, obesity, atrial fibrillation and paced rhythm, or those with NT‐proBNP values in the grey zone.

show abstract

Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure

Abstract: Midregional proANP is an independent predictor of mortality in patients with chronic HF. Midregional proANP adds prognostic information to NT-proBNP.

Cited by 140 publications

References 25 publications

Prognostic Value of Midregional Pro–A-Type Natriuretic Peptide and N-Terminal Pro–B-Type Natriuretic Peptide in Patients with Stable Coronary Heart Disease Followed over 8 Years

Prognostic Value of Midregional Pro–A-Type Natriuretic Peptide and N-Terminal Pro–B-Type Natriuretic Peptide in Patients with Stable Coronary Heart Disease Followed over 8 Years

Comparison of Midregional Pro–A-Type Natriuretic Peptide and the N-Terminal Pro–B-Type Natriuretic Peptide for Predicting Mortality and Cardiovascular Events

Comparative accuracy of NT‐proBNP and MR‐proANP for the diagnosis of acute heart failure in dyspnoeic patients

Contact Info

Product

Resources

About